Alexandra Canori

Alexandra Canori

Auto-generated profile, based on publicly available information

Alexandra Canori

Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai , New York, NY 10029

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2023 in Journal of Rehabilitation and Assistive Technologies Engineering
Verified
Journal Article
Open access
ACAlexandra Canori
Alexandra Canori
RLRithika Lakshminarayanan
Rithika Lakshminarayanan
MNMelissa Nunn
Melissa Nunn
MSMary Schmidt-Read
Mary Schmidt-Read
SIStephen S Intille
Stephen S Intille
SHShivayogi Hiremath
Shivayogi Hiremath
Introduction: Many barriers to physical activity (PA) exist for individuals with spinal cord injury (SCI). Social engagement may improve motivation to perform PA, which in turn may increase PA levels. This pilot study investigates how social engagement facilitated by mobile technology may reduce lack of motivation as a barrier to PA in individuals with SCI and demonstrates design implications for future technologies. Methods: A user-needs survey was conducted with participants in the community. We recruited 26 participants (16 individuals with SCI and 10 family members or peers). A participatory design process using semi-structured interviews was used to identify themes relating to PA barriers. Results: One theme related to PA barriers was lack of PA-focused forums to connect with peers. Participants with SCI considered connecting with other individuals with SCI more motivating than connecting with their family members. Another key finding was that participants with SCI did not perceive that personal fitness trackers were targeted towards wheelchair-based activities. Conclusions: Engagement and communication with peers who have similar functional mobility levels and life experiences can potentially improve motivation for PA; however, PA-motivational platforms are not tailored towards wheelchair-users. Our preliminary findings show that some individuals with SCI are not satisfied with current mobile-technologies for wheelchair-based PA.

23 March 2026 in medRxiv
Verified
Preprint
Open access
PDF file
ACAlexandra Canori
Alexandra Canori
EWEric Watson
Eric Watson
DPDevanshi Patel
Devanshi Patel
AFArianna Fiorentino
Arianna Fiorentino
CSChristopher Santiago
Christopher Santiago
JBJacqueline Becker
Jacqueline Becker
Background: Cognitive impairment has significant implications for function and quality of life and is common in individuals with post-acute sequelae of SARS CoV-2, also known as long COVID (LC). Emerging evidence suggests that sustained neuroinflammation, cerebrovascular dysfunction, and mitochondrial impairment are contributors to cognitive symptoms. Microtesla Magnetic Therapy (MMT) is a low-amplitude radiofrequency magnetic field intervention that has demonstrated anti-inflammatory and neuroprotective effects in preclinical models, suggesting it may be valuable in the management of cognitive impairment from LC and other neurological disorders. This study is the first randomized controlled trial to evaluate MMT for LC-related cognitive impairment. Objective: To evaluate the feasibility, safety, and preliminary efficacy of an at-home MMT intervention in individuals with moderate-to-severe cognitive impairment from LC. Methods: In this prospective feasibility study, 30 participants with LC-related cognitive impairment were randomized (2:1) to receive active or sham MMT. Participants self-administered 15-minute treatments at home with remote monitoring twice weekly for 4 weeks using a head-worn device that delivered a nonthermal radiofrequency magnetic field to the whole brain. Feasibility was defined as completion of at least 80% of prescribed treatments and all study visits. Secondary outcomes included safety, cognitive function, and self-reported mood and quality of life assessed at baseline, post-treatment (Week 4), and follow-up (Week 8). Results: Feasibility was high, with 100% treatment adherence among participants who completed the study and strong usability ratings for at-home administration. There were no device-related adverse events. Compared with sham, participants receiving active MMT showed significantly greater improvements from baseline to Week 8 in WAIS-IV Digit Span Sequencing (p= 0.026), HVLT-R Recall (p= 0.044), and D-KEFS Color Naming (p= 0.049). Additional measures of attention, processing speed, and executive function demonstrated favorable trends in the active group. Emotional well-being, assessed by the SF-36, improved significantly in the active group at Week 8 compared with sham (p= 0.017), and mood symptoms showed clinically meaningful improvement. Conclusions: Administration of the MMT intervention at home was feasible, safe, and well tolerated in individuals with cognitive impairment from LC. Preliminary findings suggest sustained clinically meaningful improvements in multiple cognitive domains and mood following treatment.

1 September 2026 in Brain Communications
Verified
Journal Article
Open access
ACAlexandra Canori
Alexandra Canori
EWEric Watson
Eric Watson
DPDevanshi Patel
Devanshi Patel
AFArianna Fiorentino
Arianna Fiorentino
CSChristopher Santiago
Christopher Santiago
JBJacqueline Becker
Jacqueline Becker
Cognitive impairment is common in post-acute sequelae of severe acute respiratory syndrome coronavirus 2 infection (long COVID) and substantially affects function and quality of life. Evidence suggests that sustained neuroinflammation, cerebrovascular dysfunction and mitochondrial impairment contribute to cognitive symptoms. Microtesla Magnetic Therapy (MMT) is a transcranial, low-amplitude radiofrequency magnetic field intervention that has shown anti-inflammatory and neuroprotective effects in preclinical models, suggesting potential value in long COVID and other neurological disorders. This is the first randomized controlled trial of MMT for long COVID cognitive impairment. We evaluated the feasibility (primary) and safety (secondary) of at-home MMT in individuals with objective cognitive impairment from long COVID. Thirty participants were randomized 2:1 to active or sham MMT and self-administered 15-min treatments at home twice weekly for 4 weeks, with remote monitoring, using a head-worn device delivering a non-thermal radiofrequency magnetic field to the whole brain. Feasibility was defined as completing at least 80% of prescribed treatments and all study visits. Safety was assessed by adverse events. Cognitive function and self-reported mood and quality of life were exploratory outcomes assessed at baseline, Week 4 (post-treatment) and Week 8 (follow-up). Feasibility was high: all participants who completed the study adhered to 100% of treatments, and usability ratings were strong. No device-related adverse events occurred. Compared with sham, active MMT participants showed significantly greater improvement from baseline to Week 8 in Wechsler Adult Intelligence Scale Digit Span Sequencing (P = 0.026), Hopkins Verbal Learning Test–Revised Total Recall (P = 0.044) and Delis-Kaplan Executive Function System Color Naming (P = 0.049). Other measures of attention, processing speed and executive function did not differ significantly between groups. Emotional well-being on the 36-Item Short Form Survey improved significantly more with active MMT at Week 8 (P = 0.017). Depression and anxiety decreased in both groups; the anxiety reduction was greater with active treatment in the linear mixed-effects model (week × treatment interaction, P = 0.038) but not in the between-group change score comparison (P = 0.057). At-home MMT was feasible, safe and well tolerated in individuals with cognitive impairment from long COVID. These preliminary, exploratory findings showed nominally significant between-group differences favouring active treatment on selected cognitive measures and emotional well-being and require confirmation in larger, adequately powered trials.

1 October 2021 in Archives of Physical Medicine and Rehabilitation
Verified
Journal Article
Closed access
PDF file
ACAlexandra Canori
Alexandra Canori
RLRithika Lakshminarayanan
Rithika Lakshminarayanan
APAditya Ponnada
Aditya Ponnada
SIStephen Intille
Stephen Intille
SHShivayogi Hiremath
Shivayogi Hiremath

27 August 2026 in medRxiv
Verified
Preprint
Open access
PDF file
NBNathan R. Brady
Nathan R. Brady
ACAlexandra Canori
Alexandra Canori
DMDavid Maltz
David Maltz
DKDouglas Y. Kirsher
Douglas Y. Kirsher
WZWenyu Zhou
Wenyu Zhou
BGBlake T. Gurfein
Blake T. Gurfein
Cognitive impairment is a disabling feature of Long COVID with no established disease-modifying therapy, and little is known about the biological changes accompanying clinical improvement. Microtesla Magnetic Therapy (MMT) is a low amplitude radiofrequency electromagnetic field intervention delivered to the whole brain. In a randomized, sham-controlled feasibility trial, at home MMT was feasible, safe, and well tolerated, with evidence of clinical improvement among treated participants. We explored molecular changes associated with response using SomaScan 11K plasma proteomics on paired baseline and week 4 samples. Participants were classified post hoc within each treatment arm using a clinician-selected response phenotype integrating cognitive and symptom domains. These groups were used for proteomic, pathway, and OrganAge analyses. MMT response was associated with selective proteome remodeling and an exploratory 17 protein response pattern in which Hedgehog interacting protein (HHIP), a Hedgehog signaling antagonist, was most strongly associated with response. Directional pathway analysis identified patterns consistent with lower inflammatory and injury biology and higher repair and adaptive remodeling. OrganAge analysis showed trends toward lower Brain and Organismal OrganAge with MMT. These findings prioritize HHIP and the exploratory 17 protein response pattern for prospective validation and support evaluation of plasma proteomics for monitoring treatment response.